Antibe Therapeutics Inc.

Antibe Therapeutics Inc develops safer, non-addictive medicines for pain and inflammation. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. The company’s drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Its operating segment includes Antibe and Citagenix. The company generates maximum revenue from Citagenix segment and geographically from Canada. Citagenix segment is a marketer and distributor of regenerative medicines serving the dental and orthopaedic market places.

Antibe Therapeutics Inc. News